<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03861143</url>
  </required_header>
  <id_info>
    <org_study_id>BT-11-201</org_study_id>
    <nct_id>NCT03861143</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Oral BT-11 in Mild to Moderate Ulcerative Colitis</brief_title>
  <official_title>A Randomized , Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate Efficacy and Safety of Oral BT-11 in Mild to Moderate Ulcerative Colitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Landos Biopharma Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Landos Biopharma Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 2 randomized, placebo-controlled, double-blind, parallel-group multicenter
      study with an optional open-label extension (OLE) period. The purpose of this study is to
      evaluate the efficacy and safety of oral BT-11 compared to placebo in subjects with mild to
      moderate UC. This study includes 3 periods: induction, maintenance, and an optional OLE
      period.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Following a 28-day screening period, a total of 195 subjects with mild to moderate UC (total
      Mayo Score 4-10; Mayo endoscopic subscore [MES] ≥ 2) are planned to be enrolled into this
      study from approximately 46 sites in Europe and the United States. Eligible subjects will be
      randomized in a 1:1:1 ratio to receive BT-11 low-dose (500 mg), BT-11 high-dose (1,000 mg) or
      placebo. Each of the treatment arms will comprise 65 subjects. The randomization will be
      stratified by prior exposure to biologic therapy for UC (yes/no; exposed population limited
      to 30% of total sample) and corticosteroid use at baseline (yes/no).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 14, 2019</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is a phase 2 randomized, placebo-controlled, double-blind, parallel-group multicenter study with an optional open label extension (OLE) period. The purpose of this study is to evaluate the efficacy and safety of oral BT-11 compared to placebo in subjects with mild to moderate UC. This study includes 3 periods: induction, maintenance, and an optional OLE period.
Following a 28-day screening period, a total of 195 subjects with mild to moderate UC (total Mayo Score 4-10; Mayo endoscopic subscore [MES] ≥ 2) are planned to be enrolled into this study from approximately 46 sites in Europe and the United States. Eligible subjects will be randomized in a 1:1:1 ratio to receive BT-11 low-dose (500 mg), BT-11 high-dose (1,000 mg) or placebo. Each of the treatment arms will comprise 65 subjects. The randomization will be stratified by prior exposure to biologic therapy for UC (yes/no; exposed population limited to 30% of total sample) and corticosteroid use at baseline (yes/no).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical remission rate</measure>
    <time_frame>12 weeks</time_frame>
    <description>Clinical remission defined by total Mayo score ≤ 2 with all subscores ≤ 1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Endoscopic remission rate</measure>
    <time_frame>12 weeks</time_frame>
    <description>Mayo endoscopic subscore [MES] of 0 or 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mucosal healing rate</measure>
    <time_frame>12 weeks</time_frame>
    <description>MES of 0 or 1 and a Geboes Histologic Index score of less than 3.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in fecal calprotectin from baseline</measure>
    <time_frame>up to 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of BT-11 in feces</measure>
    <time_frame>up to 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events</measure>
    <time_frame>up to 12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">195</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>BT-11 low-dose (500 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BT-11 high-dose (1,000 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BT-11 (500 mg)</intervention_name>
    <description>Subjects will be randomized to receive BT-11 low-dose (500 mg) once-daily for 12 weeks. All tablets administered (placebo and BT-11) will have the same appearance and size. Each subject will receive blister packs of the study drug (high-dose BT-11, low-dose BT-11, or placebo).</description>
    <arm_group_label>BT-11 low-dose (500 mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BT-11 (1000 mg)</intervention_name>
    <description>Subjects will be randomized to receive BT-11 low-dose (1000 mg) once-daily for 12 weeks. All tablets administered (placebo and BT-11) will have the same appearance and size. Each subject will receive blister packs of the study drug (high-dose BT-11, low-dose BT-11, or placebo).</description>
    <arm_group_label>BT-11 high-dose (1,000 mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subjects will be randomized to receive Placebo once-daily for 12 weeks. All tablets administered (placebo and BT-11) will have the same appearance and size. Each subject will receive blister packs of the study drug (high-dose BT-11, low-dose BT-11, or placebo).</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. . Male and female subjects aged 18 to 75 years, inclusive.

          2. . Diagnosis of UC for at least 3 months prior to screening.

          3. . Mild to moderate UC, as defined by a total Mayo Score of 4 to I 0 inclusive at
             baseline with a MES 2 (confirmed by central reader).

          4. . If subjects have previously received biologic therapy for UC (i.e., tumor necrosis
             factor [TNF] antagonists, vedolizumab or ustekinumab), they must have a washout period
             of 8 weeks prior to randomization, and any previous failure of biologic treatment is
             limited to only one class of biologic. (Note: this inclusion criterion is only
             applicable until 58 subjects with prior exposure to biologic therapy have been
             randomized).

          5. . If subjects are receiving the following UC treatments, they must be on a stable dose
             for at least I month prior to random ization: 5- aminosal icylates (5-ASAs) (not
             exceed i ng 4.8 g per day), oral corticosteroids (not exceeding prednison e 20 mg,
             budesonide 9 mg, or equivalent).

          6. . If subjects are receiving bile-salt sequestrant, they must be on a stable dose for
             at least 3 months prior to randomization.

          7. . If subjects are receiving any non-prohibited medications, they must agree to
             maintain stable doses of concomitant medication s for UC for the duration of the
             trial.

          8. . Unlikely to conceive, as defined by 1 of the following: a) subject is surgically
             sterilized female, (b) subject is postmenopausal female 2: 45 years of age with
             clinical documentation of menopause (i.e., 12 months without menses), or c) matter is
             male or subject is woman of childbearing potential (WOCBP), and agrees to abstain from
             heterosexual activity, use adequate hormonal contraception, or use double barrier
             contraception.

          9. . For WOCBP, the subject must have a negative pregnancy test at screening and within
             24 hours prior to the first dose of study drug.

         10. . Able to participate fully in all aspects of this clinical trial.

         11. . Written informed consent must be obtained and documented.

        Exclusion Criteria:

          1. ). A diagnosis of CD, indeterminate colitis, or presence or history of the fistula
             with CD.

        (2). Severe UC as per modified Truelove and Witts criteria (2: 6 bloody stools per day and
        one or more of the following: pulse &gt; 90 bpm, temperature &gt; 37.8°C, hemoglobin &lt; 10.5 g/dl,
        or hs-CRP &gt; 30 mg/I).

        (3). Disease activity limited to distal 15 cm (proctitis).

        (4). Treatment with an immunosuppressant (azathioprine, 6- mercaptopurine [6-MP]) within 25
        days prior to randomization.

        (5). History of toxic megacolon, abdominal abscess, symptomatic colonic stricture, or
        stoma; history or is at imminent risk of colectomy.

        (6). History or current evidence of colonic dysplasia or adenomatous colonic polyps.

        (7). Current bacterial or parasitic pathogenic enteric infection, including Clostridium, d
        difficult, known infection with hepatitis B or C virus, known infection with human
        immunodeficiency virus, infection requiring hospitalization or intravenous s antimicrobial
        therapy, or opportunistic infection within 6 months prior to screening, any infection
        requiring antimicrobial therapy within 2 weeks prior to screening, history of more than I
        episode of herpes zoster or any episode of disseminated zoster.

        (8). Live virus vaccination within 1 month prior to screening.

        (9). Treatment with cyclosporine, mycophenolate, tacrolimus, or tofacitinib within 4 weeks
        prior to randomization.

        (10). Treatment with intravenous corticosteroids, rectal corticosteroids, or rectal 5-ASA
        within 2 weeks prior to randomization.

        (11). Fecal microbiota transplantation within 1 month prior to screening.

        (12). A concurrent clinically significant, unstable, or uncontrolled cardiovascular,
        pulmonary, hepatic, renal, Gl, genitourinary, hematological, coagulation, immunological,
        endocrine/metabolic, or other medical disorder that, in the opinion of the investigator,
        might confound the study results or poses additional risk to the subject.

        (13). Known primary or secondary immunodeficiency.

        (14). History of myocardial infarction, unstable angina, transient ischemic attack,
        decompensated heart failure requiring hospitalization, congestive heart failure (New York
        Health Association [NYHA] Class 3 or 4), uncontrolled arrhythmias, cardiac
        revascularization, stroke, uncontrolled hypertension, or uncontrolled diabetes within 6
        months of screening.

        (15). Laboratory abnormalities at screening, as determined and documented by the
        investigator.

        (16). Pregnant or lactating females.

        (17). Any surgical procedure anesthesia within I month prior to screening, or planned
        elective surgery during the study.

        (18). History of malignant neoplasms or carcinoma in situ within 5 years prior to
        screening.

        (19). Current or recent history of alcohol dependence or illicit drug use that in the
        opinion of the investigator may interfere with the subject's ability to comply with the
        study procedures.

        (20). Mental or legal incapacitation at the time of screening visit or a history of
        clinically significant psychiatric disorders that would impact the ability to participate
        in the trial according to the investigator.

        (21). Unable to attend study visits or comply with procedures.

        (22). Concurrent participation in any other interventional study.

        (23). Received any investigational therapy within 30 days of initiation of study drug.

        (24). Serious underlying disease other than UC that in the opinion of the investigator may
        interfere with the subject's ability to participate fully in the study.

        (25). Previous exposure to BT-11.

        (26). Prior enrollment in the current study and had received study treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jyoti Chauhan</last_name>
    <role>Study Director</role>
    <affiliation>Landos Biopharma Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Josep Bassaganya Riera</last_name>
    <phone>5402182232</phone>
    <email>jbr@landosbiopharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jyoti Chauhan</last_name>
    <email>jyoti@landosbiopharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Axis Clinical Trials</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90036</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Lydie Hazan</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ventura Clinical Trials</name>
      <address>
        <city>Ventura</city>
        <state>California</state>
        <zip>93003</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabine Steinberg-Hazan, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medycal Research Inc.</name>
      <address>
        <city>Brooksville</city>
        <state>Florida</state>
        <zip>34613</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Salman Muddassir, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Invesclinic.U.S,LLC.FL</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernard Garcia</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Florida Research Institute</name>
      <address>
        <city>Lakewood Ranch</city>
        <state>Florida</state>
        <zip>34211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arun Khazanchi, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Delta Research Partners LLC</name>
      <address>
        <city>Monroe</city>
        <state>Louisiana</state>
        <zip>71201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bal Raj Bhandari</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Atrium Health- Center for Digestive Health</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hanson John, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Consultants for Clinical Research</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pradeep Bekal</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>HD Research Corp.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Alan Skolnick</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Discovery MM Services, Inc.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77061</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caroline Mbogua, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Invesclinic.U.S,LLC.</name>
      <address>
        <city>McAllen</city>
        <state>Texas</state>
        <zip>78503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valeska Balderas, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Discovery MM Services, Inc.</name>
      <address>
        <city>Missouri City</city>
        <state>Texas</state>
        <zip>77459</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deirdre McMullen, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institution &quot;Gomel Regional Clinical Hospital&quot;</name>
      <address>
        <city>Gomel</city>
        <zip>246029</zip>
        <country>Belarus</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prof. Elena Mikhailova</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Healthcare Institution &quot;Vitebsk Regional Clinical Hospital&quot;</name>
      <address>
        <city>Vitebsk</city>
        <zip>210037</zip>
        <country>Belarus</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prof. Pimanov Sergey</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Clinical Center of the Republic of Srpska, Department of gastroenterology and hepatology</name>
      <address>
        <city>Banja Luka</city>
        <zip>78000</zip>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Mladen Djurdjevic</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Clinical Hospital Mostar, Internal Medicine Clinic with Dialysis Center</name>
      <address>
        <city>Mostar</city>
        <zip>88000</zip>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ante Bogut, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>General Hospital &quot;Prim. Dr. Abdulah Nakas&quot;, Department of General Internal Medicine and Gastroenterology</name>
      <address>
        <city>Sarajevo</city>
        <zip>71000</zip>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amir Selimagic, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cantonal Hospital Zenica, Gastroenterology</name>
      <address>
        <city>Zenica</city>
        <zip>72000</zip>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elmedin Lacic</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Polyclinic Duvnjak</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prof. Zeljko Cabrijan</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Polyclinic Duvnjak</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prof. Marko Duvnjak</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Curatio</name>
      <address>
        <city>Tbilisi</city>
        <zip>0114</zip>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margalita Khazaradze, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>High Technology Medical Center University Clinic</name>
      <address>
        <city>Tbilisi</city>
        <zip>0144</zip>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giorgi Samadashvili</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aversi Clinic ltd.</name>
      <address>
        <city>Tbilisi</city>
        <zip>0160</zip>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tengiz Telia</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>David Abuladze Georgian- Italian Clinic</name>
      <address>
        <city>Tbilisi</city>
        <zip>0179</zip>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tamar Gegeshidze</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Endomedix Ltd, Endomedix Diagnostic Centres Budapest</name>
      <address>
        <city>Budapest</city>
        <zip>1139</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alajos Takats, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Debrecen, Clinical Centre</name>
      <address>
        <city>Debrecen</city>
        <zip>4031</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prof Istvan Altorjay, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bugat Pal Hospital</name>
      <address>
        <city>Gyöngyös</city>
        <zip>3200</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gyula Horvat</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pandy Kalman Bekes County Hospital</name>
      <address>
        <city>Gyöngyös</city>
        <zip>5700</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ilona Fazekas, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Petz Aladár County and Teaching Hospital</name>
      <address>
        <city>Győr</city>
        <zip>H-9024</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Istvan Racz</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Szent Borbala Hospital</name>
      <address>
        <city>Tatabánya</city>
        <zip>2800</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andras Kafony, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Republican Clinical Hospital Arensia EM Unit</name>
      <address>
        <city>Chisinau</city>
        <zip>MD-2025</zip>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Raisa Tanase</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>BioVirtus Research Site Sp. z o.o.</name>
      <address>
        <city>Józefów</city>
        <zip>05-410</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prof. Maria Orzeszko</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Promed</name>
      <address>
        <city>Kraków</city>
        <zip>31-513</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Danuta Owczarek</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>KO-MED Centra Kliniczne</name>
      <address>
        <city>Puławy</city>
        <zip>24-100</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Łukasz Wolański</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Endoskopia Sp. z o.o.</name>
      <address>
        <city>Sopot</city>
        <zip>81-756</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Marek M Horyński</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>WIP Warsaw IBD Point Profesor Kierkus</name>
      <address>
        <city>Warsaw</city>
        <zip>00-728</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prof. Jarosław Kierkuś</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>European Institute for Family Health</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Leningradskaya Region</state>
        <zip>196657</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Inna Pakhomova, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>LLC Trekhgorka Medicine</name>
      <address>
        <city>Odintsovo</city>
        <state>Moscow Region</state>
        <zip>143005</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Evgeny Soldatskiy, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ulyanovsk Regional Clinical Hospital</name>
      <address>
        <city>Ulyanovsk</city>
        <state>Ulyanovsk Region</state>
        <zip>432063</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daria Varganova</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>JSC Medical Technologies</name>
      <address>
        <city>Ekaterinburg</city>
        <zip>620075</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marina Karakina</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Diagnostic Centre &quot;Ultramed&quot;</name>
      <address>
        <city>Omsk</city>
        <zip>644024</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valentina Molovstova</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>ArsVitae Medical Centre</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>194223</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Irina Yarovenko</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Centre of Serbia, Clinic for gastroenterology and hepatology</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Aleksandra Pavlovic Markovic, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital Centre &quot;Dr Dragisa Misovic-Dedinje&quot;, Department for Digestive Endoscopy</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Aleksandra Pavlovic</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Military Medical Academy, Clinic for Gastroenterology and Hepatology</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Nebojsa Manojlovic</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Centre Kragujevac, Clinic for Internal Medicine, Department for Gastroenterohepatology</name>
      <address>
        <city>Kragujevac</city>
        <zip>34000</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Biljana Milojkovic Kicevska, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Municipal Non-profit Enterprise &quot;City Clinical Hospital No. 2 named after Prof. O. O. Shalimov&quot; of Kharkiv City Council, Proctology Department, Kharkiv</name>
      <address>
        <city>Kharkiv</city>
        <zip>61037</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Olena Datsenko</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Belarus</country>
    <country>Bosnia and Herzegovina</country>
    <country>Croatia</country>
    <country>Georgia</country>
    <country>Hungary</country>
    <country>Moldova, Republic of</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>February 27, 2019</study_first_submitted>
  <study_first_submitted_qc>February 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 4, 2019</study_first_posted>
  <last_update_submitted>May 18, 2020</last_update_submitted>
  <last_update_submitted_qc>May 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

